Novo Nordisk’s Sogroya Wins FDA Approval for Children With Turner Syndrome
The once-weekly, long-acting growth hormone is approved for appropriate children aged 2.5 and older.
The once-weekly, long-acting growth hormone is approved for appropriate children aged 2.5 and older.